Clinical efficacy of gangliosides on premature infants suffering from white matter damage and its effect on the levels of IL‑6, NSE and S100β

Wang, Xiaopeng; Tian, Xiuying; Ma, Junling; Zheng, Jun

doi:10.3892/etm.2019.7539

Cited by 4 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 1 year, the group of children treated with ganglioside had an IQ higher than the control group in the aspects of social adaptation, gross motor, fine motor, language and personal social contact. Importantly, no side effects were reported in GM1 receiving infants [169].…”

Section: Gm1 In Brain Damage Of Premature Infantsmentioning

confidence: 92%

“…Recently, a small clinical study was conducted in China on a series of 76 premature infants where the treatment with GM1 administered intravenously for 14 days resulted in a significant reduction in the damage to white matter around the cerebral ventricles after 7 and 14 days after birth compared to controls subjected to the standards of care [169]. At the same time points, there was a stronger reduction in serum levels of IL-6, neuronal specific enolase NSE and S100β in the group of children receiving GM1 compared to controls.…”

Section: Gm1 In Brain Damage Of Premature Infantsmentioning

confidence: 99%

See 1 more Smart Citation

GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration

Chiricozzi

Lunghi

Biase

et al. 2020

IJMS

102

140

View full text Add to dashboard Cite

Many species of ganglioside GM1, differing for the sialic acid and ceramide content, have been characterized and their physico-chemical properties have been studied in detail since 1963. Scientists were immediately attracted to the GM1 molecule and have carried on an ever-increasing number of studies to understand its binding properties and its neurotrophic and neuroprotective role. GM1 displays a well balanced amphiphilic behavior that allows to establish strong both hydrophobic and hydrophilic interactions. The peculiar structure of GM1 reduces the fluidity of the plasma membrane which implies a retention and enrichment of the ganglioside in specific membrane domains called lipid rafts. The dynamism of the GM1 oligosaccharide head allows it to assume different conformations and, in this way, to interact through hydrogen or ionic bonds with a wide range of membrane receptors as well as with extracellular ligands. After more than 60 years of studies, it is a milestone that GM1 is one of the main actors in determining the neuronal functions that allows humans to have an intellectual life. The progressive reduction of its biosynthesis along the lifespan is being considered as one of the causes underlying neuronal loss in aged people and severe neuronal decline in neurodegenerative diseases. In this review, we report on the main knowledge on ganglioside GM1, with an emphasis on the recent discoveries about its bioactive component.

show abstract

Section: Gm1 In Brain Damage Of Premature Infantsmentioning

confidence: 92%

Section: Gm1 In Brain Damage Of Premature Infantsmentioning

confidence: 99%

GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration

Chiricozzi

Lunghi

Biase

et al. 2020

IJMS

102

140

View full text Add to dashboard Cite

show abstract

“…Thus, restoration of CSF-BBB function is correlated with better S100β passage and neurological functioning. [ 35 ] Similarly, Branco et al . [ 36 ] illustrated that serum level of S100β in the first 48 h in AIS predicts functional outcome at 12 weeks, regarding 150 ng/L as a cutoff value.…”

Section: Discussionmentioning

confidence: 99%

Statin therapy associated with decreased neuronal injury measured by serum S100β levels in patients with acute ischemic stroke

Al-Kuraishy

Al-Gareeb

Naji

2021

International Journal of Critical Illness and Injury Science

View full text Add to dashboard Cite

Background: Acute ischemic strokes (AIS) are a common cause of morbidity, mortality, and disability. The serum biomarker S100β correlates with poor neurological outcomes in the setting of AIS. This study describes the impact of statin treatment on S100β levels following AIS. Methods: This was a prospective case–control study of AIS patients compared to healthy controls. Patients were stratified into three groups: (1) AIS patients on statin therapy, (2) AIS patients not on statin therapy, and (3) healthy controls. Demographics, clinical parameters, stroke risk scores (SRS), and S100β levels were recorded for all patients. Results: Blood pressure, lipids, and SRS scores were higher in stroke versus control patients (all P < 0.05), and lower in Group I versus II (all P < 0.05). S100β levels were higher in stroke versus nonstroke patients ( P = 0.001), and lower in Group I versus II ( P = 0.001). Furthermore, patients on atorvastatin showed greater S100β reductions than those on rosuvastatin therapy ( P = 0.01). Conclusion: In acute stroke patients, statins therapy correlated with reductions in the neuronal injury biomarker S100β, with greater reductions observed for atorvastatin than rosuvastatin therapy.

show abstract

“…Numerous clinical trials have been performed to verify GM1-mediated recovery in Parkinson’s disease (subcutaneous injection) [ 33 ], Alzheimer’s disease (intracranial administration) [ 32 ], spinal cord injury (intravenous injection) [ 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 ], in brain damage of premature infants (intravenous injection) [ 55 ], and in ischemic strokes of adult patients (intravenous injection) [ 56 ]. Results are difficult to correctly interpret because the expected end points have often not been reached, both due to the limited number of patients and due to the disease being at different stages among the different experimental groups.…”

Section: Gm1 Oligosaccharide (Oligogm1): the Future Treatment For Neu...mentioning

confidence: 99%

Gangliosides and the Treatment of Neurodegenerative Diseases: A Long Italian Tradition

et al. 2022

View full text Add to dashboard Cite

Gangliosides are glycosphingolipids which are particularly abundant in the plasma membrane of mammalian neurons. The knowledge of their presence in the human brain dates back to the end of 19th century, but their structure was determined much later, in the middle of the 1950s. From this time, neurochemical studies suggested that gangliosides, and particularly GM1 ganglioside, display neurotrophic and neuroprotective properties. The involvement of GM1 in modulating neuronal processes has been studied in detail by in vitro experiments, and the results indicated its direct role in modulating the activity of neurotrophin-dependent receptor signaling, the flux of calcium through the plasma membrane, and stabilizing the correct conformation of proteins, such as α-synuclein. Following, in vivo experiments supported the use of ganglioside drugs for the therapy of peripheral neuropathies, obtaining very positive results. However, the clinical use of gangliosides for the treatment of central neurodegeneration has not been followed due to the poor penetrability of these lipids at the central level. This, together with an ambiguous association (later denied) between ganglioside administration and Guillain-Barrè syndrome, led to the suspension of ganglioside drugs. In this critical review, we report on the evolution of research on gangliosides, on the current knowledge on the role played by gangliosides in regulating the biology of neurons, on the past and present use of ganglioside-based drugs used for therapy of peripheral neuropathies or used in human trials for central neurodegenerations, and on the therapeutic potential represented by the oligosaccharide chain of GM1 ganglioside for the treatment of neurodegenerative diseases.

show abstract

Clinical efficacy of gangliosides on premature infants suffering from white matter damage and its effect on the levels of IL‑6, NSE and S100β

Cited by 4 publications

References 17 publications

GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration

GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration

Statin therapy associated with decreased neuronal injury measured by serum S100β levels in patients with acute ischemic stroke

Gangliosides and the Treatment of Neurodegenerative Diseases: A Long Italian Tradition

Contact Info

Product

Resources

About